In future clinical applications of R-iEOs, the intervention and therapy regarding the CRS could refer to CAR-T cell adoptive therapy by using anti-IL6 antibody (e.g., Tocilizumab), corticosteroids (e.g., dexamethasone) or other related approaches [50]. Here, IL6 is linked to congenital rubella syndrome.